Live Attenuated Influenza Vaccine

Live Attenuated Influenza Vaccine (LAIV) is a nasal spray vaccine that helps protect against influenza, commonly known as the flu. It is a combination medication containing weakened (live) strains of the influenza virus, which have been modified to be less harmful. The vaccine is designed to stimulate the immune system to produce antibodies against the specific strains of the virus, providing immunity and reducing the severity of the illness if exposed to the virus in the future.
The LAIV vaccine is typically administered to individuals aged 2 to 49 years, with no history of severe allergic reactions to the vaccine or its components. The vaccine may not protect against all strains of the influenza virus, and its effectiveness may vary from year to year. The vaccine is updated annually to target the most prevalent strains of the virus circulating in the community.
The primary purpose of the Live Attenuated Influenza Vaccine is to prevent influenza infection and its complications, such as pneumonia, bronchitis, sinus infections, and ear infections. By reducing the spread of the virus, the vaccine also helps to protect vulnerable populations, such as the elderly, young children, and individuals with chronic medical conditions.